[go: up one dir, main page]

EP0818997A1 - Zusammensetzung enthaltend amiodaron und betaxolol - Google Patents

Zusammensetzung enthaltend amiodaron und betaxolol

Info

Publication number
EP0818997A1
EP0818997A1 EP96902328A EP96902328A EP0818997A1 EP 0818997 A1 EP0818997 A1 EP 0818997A1 EP 96902328 A EP96902328 A EP 96902328A EP 96902328 A EP96902328 A EP 96902328A EP 0818997 A1 EP0818997 A1 EP 0818997A1
Authority
EP
European Patent Office
Prior art keywords
amiodarone
betaxolol
pharmaceutical compositions
new pharmaceutical
compositions according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96902328A
Other languages
English (en)
French (fr)
Inventor
Soorianarain Baligagoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0818997A1 publication Critical patent/EP0818997A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide

Definitions

  • the present invention relates to the field of organic chemistry and more particularly to that of therapeutic chemistry.
  • compositions formed from a combination of a specific beta-blocking agent and amiodarone in low doses so as to avoid or limit the occurrence of annoying side effects.
  • beta-blocking agents have significant anti-arrhythmic and anti-isch ⁇ mic activity, at the usual doses, but they have the drawback of triggering significant side effects.
  • Amiodarone for its part, is an effective antiarrhythmic agent but whose sensitive side effects considerably limit its use. In general, the combination of a beta-blocker and amiodarone is contraindicated and this mention appears in all official dictionaries ⁇ cf. VIDAL).
  • Angina disease is the result of a mismatch between the heart's oxygen supply and the heart's oxygen requirements.
  • Current angina pectoris drugs have remarkable efficacy, but it is not always possible with these drugs to prevent both exertional pain and exertional arrhythmias without inducing undesirable side effects. Reducing arrhythmias during exercise is important because such arrhythmias can lead to death.
  • the objective of the invention is the creation of a very effective angina pectoris drug also possessing a certain anti-arrhythmic activity but devoid of certain side effects such as disorders of sexual function.
  • beta-blocker drugs cause headaches so intense that they stop the medication.
  • beta-blockers induce peripheral disorders, fatigue or depression EXPERIENCE
  • the beta-blocking agent selected and amiodarone paradoxically, manifest a synergistic action at these doses, which makes it possible to eliminate any side effect.
  • the daily dose of amiodarone thus administered is low enough so that the side effects which it possibly causes are considerably reduced.
  • the product alone containing the lower dose of amiodarone was designed from the quality of life scale focused on your relationship between pain and exertion. The development of this scale allowed the determination of the optimal dose.
  • the pharmaceutical compositions according to the invention significantly shift the curve of the symptoms to the left. This displacement is greater than that observed with a nitro derivative and with a calcium antagonist.
  • the invention therefore consists of new pharmaceutical compositions combining amiodarone at low doses and a blocking agent chosen from the group consisting of betaxolol and its addition salts at low doses, in combination or in mixture with an excipient or a inert non-toxic, pharmaceutically acceptable vehicle.
  • the invention therefore relates to new pharmaceutical compositions formed from a combination based on Amiodarone and a beta-blocker, characterized in that the beta-blocker is chosen from the group consisting of betaxolol and its salts. addition with a therapeutically compatible mineral or organic acid.
  • the hydrochloride effectively used in the form of a pharmaceutical specialty.
  • nitrate, phosphates, acetate, propionate, citrates, tartrates, malates, gluconates or glucose 1-phosphate find equivalent use.
  • the pharmaceutical compositions contain from 25 mg to 400 mg per unit dose of Amiodarone and more particularly from 50 mg to 100 mg.
  • the dose of betaxolol or one of its salts ranges from 2.5 mg to 75 mg per unit dose and preferably from 5 mg to 25 mg per dose. It can be lowered for intravenous administration at a dose as low as 0.5 mg.
  • the pharmaceutical compositions contain 100 mg of amiodarone and 10 mg of betaxolol or one of its salts with a therapeutically compatible mineral or organic acid.
  • beta-blocking agent the racemic molecule or a split molecule, optically active.
  • the optically active forms of beta-blocking agents exhibit the same level of activity as the racemic molecule, but on the other hand, their activity is purer, that is to say that their administration leads to fewer side effects. .
  • compositions according to the invention are intended essentially for oral administration. However, parenteral or rectal administration may be considered.
  • the most suitable forms for these routes of administration are ampoules, multidose vials, auto-injectable syringes, lyophilisates to be reconstituted with a solvent for use, bare or coated tablets, dragees, capsules, soft capsules, pills, granules, powders flavored or not, sweetened or not, suppositories or rectal capsules.
  • the appropriate inert excipient is chosen from those which are suitable for oral or rectal administration such as starches, celluloses, alkyl DClubse, carboxymethy! cellulose, lactose, calcium carbonate, calcium phosphate, magnesium phosphate, magnesium carbonate, alumina, silica, calcium silicate, magnesium silicate or talc.
  • Dispersing agents, disintegrating agents, release agents, binding agents or compression agents can be added thereto.
  • cocoa butter or semi-synthetic triglycerides or polyethylene glycol stearates are used as vehicle.
  • sugar syrup, distilled water, physiological serums, lipid emulsions or even dispersions of surfactants, nonionic agents, and generally isotonic preparations are preferably used.
  • the invention also relates to a process for obtaining the pharmaceutical compositions defined above.
  • the pharmaceutical forms according to the invention are prepared according to the usual methods of manufacture in the pharmaceutical field.
  • This product can be administered as a loading dose in the presence of severe tachycardia such as, for example, Bouveret tachycardia or a severe angina attack with ventricular extrasystoles and tachycardia.
  • severe tachycardia such as, for example, Bouveret tachycardia or a severe angina attack with ventricular extrasystoles and tachycardia.
  • the doctor can administer the ideal product as maintenance treatment with a daily dose of Amiodarone of 150 mg and a dose of Betaxolol of 10 mg.
  • the optimal product according to the invention used in the emergency treatment of acute myocardial infarction, acute ventricular tachycardia, multiple ventricular extrasystoles and tachycardia in the presence of ischemic heart disease is an intravenous form containing 0.5 mg betaxolol and 25 mg amiodarone intended to be administered within 1 to 2 minutes and which may be repeated if the tachycardia persists or until the expected results are obtained.
  • DIAGRAM 1 comparison to amiodarone
  • DIAGRAM 3 comparison to isosorbid ⁇ dinitrate
  • the new drug has fewer side effects than amiodarone and betaxolol taken alone, according to the attached table.
  • the product according to the invention is exceptionally effective on two major parameters of angina pectoris (number of angina pains and duration of painless walking). These differences are statistically significant.
  • the product according to the invention has no major side effects.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP96902328A 1996-02-02 1996-02-02 Zusammensetzung enthaltend amiodaron und betaxolol Withdrawn EP0818997A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/FR1996/000175 WO1997027850A1 (fr) 1996-02-02 1996-02-02 Compositions comprenant l'amiodarone et le betaxolol

Publications (1)

Publication Number Publication Date
EP0818997A1 true EP0818997A1 (de) 1998-01-21

Family

ID=9487981

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96902328A Withdrawn EP0818997A1 (de) 1996-02-02 1996-02-02 Zusammensetzung enthaltend amiodaron und betaxolol

Country Status (2)

Country Link
EP (1) EP0818997A1 (de)
WO (1) WO1997027850A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785995A (en) * 1997-04-11 1998-07-28 Upsher-Smith Laboratories, Inc. Pharmaceutical tablet of amiodarone salt
US20100113606A1 (en) * 2008-11-05 2010-05-06 Auspex Pharmaceuticals, Inc. Aminopropanol modulators of beta-1 adrenergic receptor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455269A (en) * 1989-03-06 1995-10-03 Baligadoo; Soorianarain Synergistic compositions of amiodarone and beta blockers
FR2726763A1 (fr) * 1994-11-10 1996-05-15 Baligadoo Soorianarain Nouveaux medicaments cardioprotecteurs et leur procede de preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9727850A1 *

Also Published As

Publication number Publication date
WO1997027850A1 (fr) 1997-08-07

Similar Documents

Publication Publication Date Title
CA2362271C (en) Essential fatty acids in the prevention of cardiovascular events
CA1328606C (fr) Emploi de la metformine, dans la preparation de medicaments
JP2014205724A (ja) 脳梗塞の予防及び治療用医薬品の製造におけるｌ−ブチルフタリドの使用
RU2001133455A (ru) Включающие циклоспорин композиции, практически не содержащие масла
WO2016188091A1 (zh) 烟酰胺单核苷酸在制备防治动脉硬化、心脑血管疾病的药物中的应用及其药物
JP2001509173A (ja) 胃腸リパーゼ阻害剤の使用
EP0629400B1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
JP3665852B2 (ja) 抗アトピー性皮膚炎組成物
MC1878A1 (fr) Compositions pharmaceutiques
EP0413694B1 (de) Pharmazeutische herzschützende zusammensetzungen enthaltend amiodaron, ein nitroderivat, nämlich isosorbiddinitrat, und gegebenenfalls einen betablocker
EP0818997A1 (de) Zusammensetzung enthaltend amiodaron und betaxolol
FR2726763A1 (fr) Nouveaux medicaments cardioprotecteurs et leur procede de preparation
WO1998040067A1 (fr) Utilisation de derives de benzofuranne pour reduire la mortalite apres infarctus du myocarde
LU85242A1 (fr) Nouvelle association medicamenteuse
JP2769217B2 (ja) 心臓状態の処置のためのプロパフェノン及びキニジンの持効性組成物
EP0489640B1 (de) Verwendung von Phenyläthanolaminotetralinen zur Herstellung eines antidepressiven und Antistress-Arzneimittels
AU2005244483B2 (en) Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease
KR20190021180A (ko) 퇴행성 신경질환 치료용 복합 제형 조성물
FR2504008A1 (fr) Preparation pharmaceutique a base d'un melange de n''-cyano-n-4-pyridyl-n'-1,2,2-trimethylpropylguanidine et d'un diuretique
EP0182772A2 (de) Arzneimittel mit verlängerter Freigabe, Verfahren zu deren Herstellung sowie deren Verwendung
US4716177A (en) Tolrestat for inhibition of weight gain
EP0307616B1 (de) Arzneimittel und Veterinärprodukt für die Behandlung der Unfruchtbarkeit
EP0412877A1 (de) Orale Arzneiform zur Verbesserung der Bioverfügbarkeit
TWI393562B (zh) 左旋丁基苯酞在製備預防和治療腦梗塞的藥物中的應用
CA2027593C (fr) Composition a activite anti-agregante plaquettaire utilisable en therapeutique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE ES GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980210